Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Anupam Rama
JPMorgan Chase & Co, Research Division

Okay. We’ll go ahead and get started. Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I’m one of the senior biotech analysts here at JPMorgan. I’m joined by my squad, Priyanka Grover, Rati Pinhe and Joyce Zhouo.

Our next presenting company is Syndax and presenting on behalf of the company, we have CEO, Michael Metzger. Michael?

Michael Metzger
CEO & Director

Thank you, Anupam. Nice to see everybody. Thanks for joining us. Thank you to JPMorgan for the invitation to present today. It’s a pleasure to be here. Pleasure to see all of you.

Let’s get started. So a reminder, today, I’m going to be making some forward-looking statements, and we’ll jump right in here. So 2025 was a transformational year for the company. We’ve transitioned successfully to a commercial stage oncology company with the launch of Revuforj and Niktimvo, 2 first and best-in-class medicines with great promise for patients. And we’ve really proven that we’ve been able to deliver for patients, 3 FDA approvals in the span of about 14 months and a very strong launch for 2 drugs. Really our bed-to-bed side — sorry, bench to bedside in about 4 years, which is sort of unprecedented speed, really shows the depth and commitment of our team to generate fantastic products, and we’re here. So we’ve generated really strong results, and we’ll talk about that today.

We have a lot of momentum going into 2026. We’re on the road to profitability with growing revenue and stable expenses. And we